{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:39:00Z","timestamp":1793853540766,"version":"4.6.1"},"reference-count":40,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia","award":["KFU250522"],"award-info":[{"award-number":["KFU250522"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Primary pseudotumor cerebri syndrome, another name for idiopathic intracranial hypertension (IIH), is a neurological condition marked by elevated intracranial pressure (ICP) that can result in papilledema without a known etiology. The purpose of this study is to compare the efficacy of topiramate and acetazolamide as medical treatments for IIH and to evaluate the long-term outcomes of both medications. Materials and Methods: This systematic review and meta-analysis followed the PRISMA guidelines and was approved by the International Prospective Register for Systematic Reviews (PROSPERO). This study included randomized clinical trials, retrospective and prospective cohort studies, and patients with idiopathic intracranial hypertension (IIH). Data extraction was performed using the Rayyan application, and the risk of bias was assessed using the Critical Appraisal Skills Program (CASP). Results: The findings revealed a statistically significant 67% increase in the likelihood of improvement at 6 months compared to the baseline with the administration of acetazolamide and topiramate. After six months of the drug administration, there was a 3.6 times decrease in visual obscuration compared to the baseline. A significant advantage of topiramate in IIH is the added benefit of weight loss, since obesity is a modifiable risk factor. However, acetazolamide remains the conventional treatment. Conclusions: This study found that acetazolamide and topiramate are both effective therapies for idiopathic intracranial hypertension (IIH), improving visual metrics and decreasing cerebrospinal fluid pressure. Topiramate aids in weight reduction, while acetazolamide is recommended for its ability to lower CSF pressure and alleviate visual changes. A combination treatment of topiramate and acetazolamide is recommended for better results.<\/jats:p>","DOI":"10.3390\/medicina61030450","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T04:58:17Z","timestamp":1741064297000},"page":"450","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness of Topiramate Versus Acetazolamide in the Management of Idiopathic Intracranial Hypertension: ASystematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6035-1230","authenticated-orcid":false,"given":"Abdullah","family":"Almaqhawi","sequence":"first","affiliation":[{"name":"Department of Family and Community Medicine, College of Medicine, King Faisal University, Al Hofuf P.O. Box 400, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Alokley","sequence":"additional","affiliation":[{"name":"Departments of Clinical Neurosciences, College of Medicine, King Faisal University, Al Hofuf P.O. Box 400, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reham","family":"Alamri","sequence":"additional","affiliation":[{"name":"College of Medicine, King Faisal University, Al Hofuf P.O. Box 400, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2779-1056","authenticated-orcid":false,"given":"Razan","family":"Alabdulqader","sequence":"additional","affiliation":[{"name":"College of Medicine, King Faisal University, Al Hofuf P.O. Box 400, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alali","sequence":"additional","affiliation":[{"name":"College of Medicine, King Faisal University, Al Hofuf P.O. Box 400, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9551-900X","authenticated-orcid":false,"given":"Ayat","family":"Aleid","sequence":"additional","affiliation":[{"name":"College of Medicine, King Faisal University, Al Hofuf P.O. Box 400, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani","family":"Alhejji","sequence":"additional","affiliation":[{"name":"College of Medicine, King Faisal University, Al Hofuf P.O. Box 400, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-089X","authenticated-orcid":false,"given":"Maryam N.","family":"ALNasser","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, College of Science, King Faisal University, Al Hofuf P.O. Box 400, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e208036","DOI":"10.1212\/WNL.0000000000208036","article-title":"Changes in prevalence of idiopathic intracranial hypertension in the United States between 2015 and 2022, stratified by sex, race, and ethnicity","volume":"102","author":"Shaia","year":"2024","journal-title":"Neurology"},{"key":"ref_2","first-page":"375","article-title":"Understanding the pathophysiology of idiopathic intracranial hypertension (IIH): A review of recent developments","volume":"95","author":"Colman","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/14737175.2015.1066675","article-title":"Acetazolamide for the treatment of idiopathic intracranial hypertension","volume":"15","author":"Supuran","year":"2015","journal-title":"Expert. Rev. Neurother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/WNO.0000000000000322","article-title":"Safety and tolerability of acetazolamide in the idiopathic intracranial hypertension treatment trial","volume":"36","author":"Hove","year":"2016","journal-title":"J. Neuro-Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/j.1468-2982.2008.01778.x","article-title":"Clinical review: The surgical treatment of idiopathic pseudotumour cerebri (idiopathic intracranial hypertension)","volume":"28","author":"Brazis","year":"2008","journal-title":"Cephalalgia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.26599\/1671-5411.2024.11.005","article-title":"The role of acetazolamide in critical care and emergency medicine","volume":"21","author":"Giamello","year":"2024","journal-title":"J. Geriatr. Cardiol. JGC"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","article-title":"An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action","volume":"41","author":"Shank","year":"2000","journal-title":"Epilepsia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/head.14897","article-title":"A randomized sequential cross-over trial evaluating five purportedly ICP-lowering drugs in idiopathic intracranial hypertension","volume":"65","author":"Mitchell","year":"2025","journal-title":"Headache J. Head Face Pain"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ajo.2017.01.004","article-title":"The Longitudinal Idiopathic Intracranial Hypertension Trial: Outcomes from Months 6\u201312","volume":"176","author":"Wall","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0404.2007.00905.x","article-title":"Treatment of idiopathic intracranial hypertension: Topiramate vs acetazolamide, an open-label study","volume":"116","author":"Celebisoy","year":"2007","journal-title":"Acta Neurol. Scand."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"The NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee, Wall, M., McDermott, M.P., Kieburtz, K.D., Corbett, J.J., Feldon, S.E., Friedman, D.I., Katz, D.M., Keltner, J.L., and Schron, E.B. (2014). Effect of Acetazolamide on Visual Function in Patients with Idiopathic Intracranial Hypertension and Mild Visual Loss. JAMA, 311, 1641.","DOI":"10.1001\/jama.2014.3312"},{"key":"ref_12","first-page":"47","article-title":"Papilledema: Epidemiology, etiology, and clinical management","volume":"7","author":"Rigi","year":"2015","journal-title":"Eye Brain"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e35545","DOI":"10.1097\/MD.0000000000035545","article-title":"Should topiramate be initial therapy in the management of idiopathic intracranial hypertension?: A literature review","volume":"102","author":"Goyal","year":"2023","journal-title":"Medicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/jama.291.8.965","article-title":"Topiramate for migraine prevention: A randomized controlled trial","volume":"291","author":"Brandes","year":"2004","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/OPTH.S27695","article-title":"Topiramate and the vision: A systematic review","volume":"6","author":"Abtahi","year":"2012","journal-title":"Clin. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.yebeh.2005.01.002","article-title":"Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy","volume":"6","author":"Fritz","year":"2005","journal-title":"Epilepsy Behav."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"s71","DOI":"10.1111\/j.1528-1157.1999.tb00922.x","article-title":"Topiramate","volume":"40","author":"Glauser","year":"1999","journal-title":"Epilepsia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/0333102418776455","article-title":"Topiramate is more effective than acetazolamide at lowering intracranial pressure","volume":"39","author":"Scotton","year":"2019","journal-title":"Cephalalgia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jocn.2020.04.066","article-title":"The role of opening CSF pressure in response to treatment for idiopathic intracranial hypertension (IIH)","volume":"76","author":"Togha","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00415-022-11402-6","article-title":"The idiopathic intracranial hypertension prospective cohort study: Evaluation of prognostic factors and outcomes","volume":"270","author":"Thaller","year":"2023","journal-title":"J. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00415-017-8699-1","article-title":"Ocular ultrasound for monitoring pseudotumor cerebri syndrome","volume":"265","author":"Lochner","year":"2018","journal-title":"J. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/ene.12512","article-title":"The course of headache in idiopathic intracranial hypertension: A 12-month prospective follow-up study","volume":"21","author":"Yri","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"999","DOI":"10.54029\/2023ijr","article-title":"Clinical, radiological profile and outcomes of patients with idiopathic intracranial hypertension: A prospective study in the South Indian population","volume":"28","author":"Azharudeen","year":"2023","journal-title":"Neurol. Asia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/01658107.2017.1400570","article-title":"Clinical and neuro-ophthalmologic predictors of visual outcome in idiopathic intracranial hypertension","volume":"42","author":"Takkar","year":"2018","journal-title":"Neuro-Ophthalmology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0333102421997093","article-title":"Diagnosis and treatment of idiopathic intracranial hypertension","volume":"41","author":"Raoof","year":"2021","journal-title":"Cephalalgia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s10194-023-01671-5","article-title":"European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention\u2014Part 3: Topiramate","volume":"24","author":"Raffaelli","year":"2023","journal-title":"J. Headache Pain"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bph.16213","article-title":"Acetazolamide and topiramate lower intracranial pressure through differential mechanisms: The effect of acute and chronic administration","volume":"181","author":"Westgate","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00701-016-3050-7","article-title":"An update on idiopathic intracranial hypertension","volume":"159","author":"Portelli","year":"2017","journal-title":"Acta Neurochir."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/jnnp-2017-317440","article-title":"Idiopathic intracranial hypertension: Consensus guidelines on management","volume":"89","author":"Mollan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11910-024-01347-w","article-title":"Novel Approaches to the Treatment of Idiopathic Intracranial Hypertension","volume":"24","author":"Subramanian","year":"2024","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12987-022-00348-6","article-title":"Acetazolamide modulates intracranial pressure directly by its action on the cerebrospinal fluid secretion apparatus","volume":"19","author":"Barbuskaite","year":"2022","journal-title":"Fluids Barriers CNS"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neulet.2017.02.032","article-title":"Acetazolamide lowers intracranial pressure and modulates the cerebrospinal fluid secretion pathway in healthy rats","volume":"645","author":"Uldall","year":"2017","journal-title":"Neurosci. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/17425255.2024.2328152","article-title":"Drug interactions of carbonic anhydrase inhibitors and activators","volume":"20","author":"Supuran","year":"2024","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/head.12997","article-title":"Topiramate in migraine prevention: A 2016 perspective","volume":"57","author":"Silberstein","year":"2017","journal-title":"Headache J. Head Face Pain"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/head.13144","article-title":"The idiopathic intracranial hypertension treatment trial: A review of the outcomes","volume":"57","author":"Smith","year":"2017","journal-title":"Headache J. Head. Face Pain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"106463","DOI":"10.1016\/j.clineuro.2020.106463","article-title":"Long term outcomes of idiopathic intracranial hypertension: Observational study and literature review","volume":"205","author":"Xu","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e000557","DOI":"10.1136\/bmjresp-2020-000557","article-title":"Side effects of acetazolamide: A systematic review and meta-analysis assessing overall risk and dose dependence","volume":"7","author":"Schmickl","year":"2020","journal-title":"BMJ Open Respir. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1007\/s12325-023-02586-y","article-title":"Narrative review of topiramate: Clinical uses and pharmacological considerations","volume":"40","author":"Pearl","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_39","first-page":"87","article-title":"Idiopathic intracranial hypertension: Ongoing clinical challenges and future prospects","volume":"ume 9","author":"Julayanont","year":"2016","journal-title":"J. Pain Res."},{"key":"ref_40","first-page":"e28513","article-title":"The ophthalmic side effects of topiramate: A review","volume":"14","author":"Mechrgui","year":"2022","journal-title":"Cureus"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/3\/450\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:46:48Z","timestamp":1760028408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/3\/450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["medicina61030450"],"URL":"https:\/\/doi.org\/10.3390\/medicina61030450","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]}}}